Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Investing Activities: 2021-2025

Historic Cash from Investing Activities for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$129.9 million.

  • SAB Biotherapeutics' Cash from Investing Activities fell 11167.05% to -$129.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.7 million, marking a year-over-year decrease of 418.09%. This contributed to the annual value of -$12.0 million for FY2024, which is 7733.63% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Cash from Investing Activities stood at -$129.9 million, which was down 2,598.52% from $5.2 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Cash from Investing Activities high stood at $11.2 million for Q2 2024, and its period low was -$129.9 million during Q3 2025.
  • In the last 3 years, SAB Biotherapeutics' Cash from Investing Activities had a median value of -$22,684 in 2023 and averaged -$12.0 million.
  • The largest annual percentage gain for SAB Biotherapeutics' Cash from Investing Activities in the last 5 years was 49,556.96% (2024), contrasted with its biggest fall of 147,126.32% (2024).
  • SAB Biotherapeutics' Cash from Investing Activities (Quarterly) stood at -$2.4 million in 2021, then skyrocketed by 95.01% to -$117,754 in 2022, then spiked by 42.37% to -$67,864 in 2023, then spiked by 13,849.21% to $9.3 million in 2024, then plummeted by 11,167.05% to -$129.9 million in 2025.
  • Its last three reported values are -$129.9 million in Q3 2025, $5.2 million for Q2 2025, and $4.7 million during Q1 2025.